Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
(firmenpresse) - Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
Leverkusen, Germany, July 25, 2016 - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that Dr. Hermann Lübbert, the Companys Chief Executive Officer, is scheduled to present at the Canaccord Genuity Annual Growth Conference, being held August 10 - 11, 2016 in Boston.
Details for the presentation are as follows:-
Date:--Wednesday, August 10, 2016
Time:--11:00AM EST
Room:--The Vancouver Room
A live-streaming webcast will be available at http://wsw.com/webcast/canaccord23/b8f.de and will be published on the Companys website shortly after the conference.
-Ends-
Enquiries, please contact: Biofrontera AG
Thomas Schaffer, Chief Financial Officer -+49 (0) 214 87 63 2 0
press(at)biofrontera.com
IR Germany: Brainwell Asset Solutions
Jürgen Benker -
+49 (0) 152 08931514
IR UK: Seton Services
Toni Vallen -
+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
PR: Kirsten Thomas -
+1 646-536-7012 / 7035
+1 508-280-6592
About Biofrontera
Biofrontera Group (FSE: B8F, ISIN DE0006046113) Biofrontera is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofronteras lead product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the U.S. in combination with its medical lamp BF-RhodoLED® for photodynamic therapy (PDT) treatment (light therapy) of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.
The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All Belixos® products are available in Europe through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
For more information, visit www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.
Leseranfragen:
Datum: 25.07.2016 - 14:27 Uhr
Sprache: Deutsch
News-ID 485045
Anzahl Zeichen: 3438
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 284 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera to Present at the Canaccord Genuity Annual Growth Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
BIOFRONTERA AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
